Search 

Hoppolek is a unique dynamic platform where children with severe disabilities can stand securely fastened. Through a mameuvre panel, the child can make the platform jump, spin or vibrate, one function at a time or all at the same time. They can also press a music button to get a feeling of dance. Hoppolek is a CE-marked medical device intended to influence the building of the skeleton. These children have through the use of Hoppolek an opportunity to independendly get to do what other children do naturally. And they like it!

KIPAX is a private investor specialized into Medtech and was founded 2010.

Investments have been made for instance into SenseAbues (breath based drug testing), Contego (Embolic Protection Devices), AEEG (Cardiac surgical devices), Zoomcamp (vehicle for disabled persons), and others.

We prefer to invest into early phase startup companies as a co-investor, but not a lead investor.

KIPAX is working in close cooperation with KIPA, a Swedish based IP firm specialized into medical devices.

KIPAX is scouting for new investemnt projects and is  this year represented by Erik Krahbichler.

KOTRA is the national trade-investment promotion agency and a governmental organization directly subordinated to the South Korean Ministry of Knowledge Economy (MKE).The main function of KOTRA in Stockholm is to promote trade and investment between Korea and Sweden.KOTRA is represented all over the world and has 113 branch
offices in 78 countries.

We would like to meet Swedish companies who are interested in business/invest in Korea.

Kuopio Innovation Ltd. is a non-profit organisation which creates national welfare by actively contributing appearance of new innovations and their effective commercialisation

KYS Invest Ltd is an investor operating in pre-seed or seed phase of health or welfare companies We have been operating in Eastern-Finland since 1995. The company is owned by City of Kuopio, Northern-Savo Health District and Itä-Suomen rahasto (Fund of Eastern-Finland).

Likvor AB

Likvor is a medical device company which has developed a system to be used in neurological investigations assessing cerebrospinal fluid (CSF) dynamics. The LIKVOR CELDA® SYSTEM is on the market today.

Product

Likvor’s core product, the CELDA® Instrument is a device to measure the dynamics of the cerebrospinal fluid (“CSF”) system. With increased understanding of the brain and neurological diseases, mapping CSF dynamics is becoming more and more important. CELDA® Instrument offers automatic and standardized protocols for multiple purposes in the diagnostic process – identifying patients suffering from normal pressure hydrocephalus (“NPH”) with dementia like symptoms, mapping CSF dynamics pre- and post-shunt surgery, shunt control, constant flow or constant pressure measurements, tap tests, bolus infusions etc. It is the first and only CE certified instrument in this field and will enable objective comparisons of research data from different clinics and research groups. With its flexibility and easy handling the CELDA® sets a new standard for investigations of CSF-dynamics. CELDA® Instrument is safer for the patient and yields a faster and more accurate diagnosis.

By using the LIKVOR CELDA® SYSTEM hospitals can make huge savings, in costs as they reduce the number of shunt reoperations, and in human suffering.

Likvor AB is marketing the LIKVOR CELDA® SYSTEM and LIKVOR CELDA® TOOLS. The system includes an instrument, a bed and a disposable tube set. The system is the result of over 40 years of research at Umeå University and Umeå University Hospital assessing cerebrospinal fluid (CSF) dynamics. The company has one patent in the US and two patents pending which includes both method and device.

Potential and the market

Statistics show that 1 in 10 dementia patients suffer from NPH. Studies indicate that approximately 1.4 million patients in Europe, USA and Japan suffer from NPH.

The CELDA® SYSTEM was CE certified in 2009, and currently there are 8 systems in clinical use with paying customers in Sweden, Denmark, Finland and the UK. To reach the European market, distributors will be used, two contracts are signed; for the German- and the UK-market. A potential clinical study in the US is being evaluated.

Next step

Likvor is looking for 20 MSK for the next three years. The capital will be used to speed up the market penetration in Europe and recruit sales personnel. Exit could be possible through an industrial buyout, for example from a shunt company.